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Summary 
Background The randomised controlled ASTIC trial showed no benefit of mobilisation and autologous haematopoietic 
stem-cell transplantation (HSCT) compared with mobilisation followed by conventional therapy using a stringent 
primary endpoint (steroid-free clinical remission for 3 months with no endoscopic or radiological evidence of intestinal 
inflammation) in patients with treatment-refractory Crohn’s disease. We now assess HSCT in patients enrolled in the 
ASTIC trial using endpoints that are traditional for clinical trials in Crohn’s disease, and identify factors that predict 
benefit or harm. 
Methods Patients who underwent mobilisation and were randomly assigned to conventional therapy in the ASTIC trial 
were offered HSCT at 1 year and underwent complete assessment for a further year. We report analyses of the combined 
cohort of patients who underwent HSCT at any time during the ASTIC trial programme. The primary outcome for this 
analysis was 3-month steroid-free clinical remission at 1 year after HSCT (Crohn’s Disease Activity Index [CDAI] <150). 
We also examined the degree of endoscopic healing at 1 year. Multivariate analysis was performed to identify factors 
associated with achieving the primary endpoint by using logistic regression, and factors associated with experiencing a 
serious adverse event using Poisson regression. Participants were not masked to treatment, but the adjudication panel 
that reviewed radiology and endoscopy was masked to allocation and visits. All patients who underwent HSCT and had 
data available at baseline and 1-year follow-up were included in the primary and safety analysis. This trial is registered 
with ClinicalTrials.gov, number NCT00297193. 
Findings Between June 28, 2007, and Sept 1, 2011, 45 patients were enrolled in the ASTIC trial from 11 European 
transplant units. 23 patients were randomly assigned to immediate HSCT, and 22 patients were assigned to 
mobilisation followed by conventional care. After completion of the ASTIC trial, 17 patients from the conventional 
care group received HSCT. In the combined cohort, data were available for 40 patients at baseline and 38 patients at 
1 year after HSCT (one patient died, one withdrew). At 1 year after HSCT, 3-month steroid-free clinical remission was 
seen in 13 (38%, 95% CI 22–55) of 34 patients with available data for the whole year. Complete endoscopic healting 
was noted in 19 (50%, 34–66) of 38 patients. On multivariate analyses, factors associated with the primary outcome 
were short disease duration (odds ratio [OR] 0·64, 95% CI 0·41–0·997 per year; p=0·048) and low baseline CDAI (0·82, 
0·74–0·98 per 10 units; p=0·031). 76 serious adverse events occurred in 23 of 40 patients with available data. The most 
common serious adverse event was infection, most of which were treatment related. Smoking and perianal disease at 
baseline were independent factors associated with the number of serious adverse events (OR 3·07 [95% CI 1·75–5·38; 
p=0·0001] for smoking and 3·97 [2·17–7·25; p<0·0001] for perianal disease) on multivariate analysis. 
Interpretation When assessed using endpoints traditional for clinical trials of conventional therapy in Crohn’s disease, 
HSCT resulted in clinical and endoscopic benefit, although it was associated with a high burden of adverse events. The 
prognostic factors identified could allow the therapy to be targeted to patients most likely to benefit and not experience 
serious adverse events. 
Funding Broad Medical Research Program, National Institute for Health Research Senior Investigator Award, The 
University of Nottingham Medical School Dean’s Fund, and The Nottingham University Hospitals NHS Trust Research 
and Development Fund. 
Introduction 
Treatment-refractory Crohn’s disease results in chronic ill health and reduced life expectancy, and often requires surgery.1–3 
Progressive inflammation and surgery result in digestive tract damage that manifests with strictures, short bowel syndrome, and 
stoma formation, and is associated with refractory non-inflammatory gastro-intestinal symptoms.1,4 Although appropriate use of 
conventional and biological therapies can induce mucosal healing, many patients have primary or secondary non-response.1,5 
Patients with treatment refractory Crohn’s disease are prepared to expose themselves to significant treatment-related risk to 
achieve remission.6 There has been considerable interest in case reports that autologous haematopoietic stem-cell transplantation 
(HSCT) can induce sustained disease remission in such patients.7–13 
The ASTIC trial compared outcomes at 1 year in 23 patients with refractory Crohn’s disease after autologous HSCT with 22 
patients undergoing stem-cell mobilisation alone followed by conventional therapy.14 The results of this trial were negative, 
and few patients in either group achieved the ambitious primary endpoint of steroid-free clinical remission for 3 months with 
no endoscopic or radiological evidence of intestinal in-flammation. However, exploratory analyses revealed that more patients 
on HSCT came off immuno-suppressive therapy, achieved clinical remission, and were free of endoscopic disease than did those 
who had mobilisation alone. HSCT was associated with many serious adverse events, including one death. Substantial morbidity 
was also associated with conventional therapy, although this therapy was associated with fewer serious adverse events.  
The benefits and risks of HSCT must be balanced against ongoing, partly effective conventional therapy. Patients who 
underwent mobilisation and were then randomly assigned to conventional therapy in the ASTIC trial were offered HSCT at 1 
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year and underwent complete assessment for a further year. We report the clinical and safety analyses of the combined cohort of 
patients who underwent HSCT at any time during the ASTIC trial programme, and establish factors associated with clinically 
relevant outcomes that are used in conventional drug trials in this disease. This report provides additional information that could 
inform future clinical trials of HSCT in refractory Crohn’s disease. 
Methods 
Study design and participants 
ASTIC was a parallel group, randomised controlled trial designed to assess the benefit and safety of autologous stem -cell 
mobilisation and HSCT compared with mobilisation followed by conventional therapy at 1 year in patients with refractory 
Crohn’s disease.14 Patients randomly assigned to conventional therapy after mobil-isation were offered HSCT after primary 
outcome assess-ment and end of follow-up. The trial was done in six European countries at 11 centres approved for allo-geneic 
transplantation by Joint Accreditation Committee of the International Society for Cellular Therapy (JACIE) and the European 
Society for Blood and Marrow Transplantation (EBMT).15 We report the clinical, radio-logical, and endoscopic out-comes 
from the com-bined cohort of all patients with assessable data at 1 year after HSCT. This includes patients initially assigned 
to an early trans-plantation and those who subsequently under-went HSCT after conventional therapy.  
The inclusion and exclusion criteria and recruitment process for the ASTIC trial have been reported previ-ously.14 Briefly, 
participants were aged 18–50 years with continuing treatment-refractory Crohn’s disease not amenable to surgery and with 
impaired quality of life (Inflammatory Bowel Disease Questionnaire [IBDQ]16 or European Quality of Life Visual analogue scale 
[EQ-VAS])17 despite at least three immunosuppressive or biological agents and corticosteroids. 
A multidisciplinary trial steering group accepted patients for inclusion and all patients provided written informed consent. The 
protocol was approved by the institutional review board at each site and complied with country-specific regulatory requirements. 
The study was done in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.18 An independent data 
and safety monitoring committee reviewed safety data after every ten patients randomly assigned or in the event of death or other 
concerns. 
Procedures 
Patients underwent protocol-designated screening in-vestigations that were reviewed by the trial steering group. Eligible 
patients underwent stem-cell mobil-isation using cyclophosphamide 2 g/m² for 2 days and non-glycosylated granulocyte 
colony stimulating factor (G-CSF, filgrastim) 10 μg/kg per day.14 Patients underwent leukapheresis when the CD34-positive 
cell count exceeded 20 × 10⁴ cells per mL to a target of 3–8 × 10⁶ CD34-positive cells per kg bodyweight and, if successful, 
underwent HSCT immediately or after a delay of 1 year. An intermediate-intensity conditioning regimen was used, made up 
of intravenous cyclo-phosphamide 50 mg/kg per day for 4 days, rabbit anti-thymocyte globulin (Genzyme, Cambridge, MA) 
2·5 mg/kg per day, and methylprednisolone 1 mg/kg per day for 3 days from day 3, with infusion of unselected autologous 
stem cells (minimum 3 × 10⁶ CD34-positive cells per kg) on day 7.15 All patients were followed up for 1 year after HSCT and 
could receive standard care for Crohn’s disease during this period, including corticosteroids, immunosuppressive agents, and 
bio-logical therapy, which were subsequently with-drawn in accordance with the protocol if appropriate. 
All patients underwent the same schedule of assessments before and during the year after HSCT. This comprised disease 
activity, haematology, bio-chemistry, and adverse events according to EBMT guidelines,15 and concomitant medication, all every 
6 weeks; quality of life (IBDQ, EQ-5D, and EQ-VAS) every 6 months; and endoscopic and radiological assessment of the entire 
intestine at baseline and 1 year. Baseline data were recorded before mobilisation in patients undergoing immediate HSCT and 
before conditioning in those undergoing HSCT at 1 year. Outcome data were recorded 1 year after conditioning for all patients. 
An adjudication committee who were masked to time of assessment and previous treatment assignment re-viewed all radiology 
and endoscopy reports to establish intestinal disease activity. 
Outcomes 
The primary endpoint for this analysis was steroid-free clinical remission. Steroid-free clinical remission was defined as a 
Crohn’s Disease Activity Index (CDAI) less than 150 with no corticosteroids for at least 3 months.19 Secondary endpoints were 
clinical and endoscopic disease activity, quality of life and a two-point patient reported outcome (PRO-2; a measure that 
comprises the stool frequency and pain score from the CDAI).20 Complete endoscopic healing was defined as an ulceration 
subscore of 0 in all segments using the Crohn’s disease simple endoscopic score (SES-CD).21 Partial endoscopic healing was 
defined as an ulceration subscore of no more than 1 in two or fewer segments of all segments examined. Patients were defined 
as free from active disease if there was no ulceration on upper gastrointestinal endoscopy, colonoscopy, and small bowel imaging, 
assessed by the adjudication committee. Endoscopic disease regression was defined as an SES-CD score of 0 in all segments. 
Baseline factors that predicted clinical and endoscopic remission as well as the occurrence of one or more serious adverse events 
were identified. 
Statistical analysis 
Quantitative variables were described using mean and SD, and compared in univariate analysis using paired or non-paired t test. 
Categorical variables were compared using χ² test or Fisher’s exact test. Multivariate analyses were done using logistic regression for 
all endpoints apart from the number of serious adverse events, which was analysed using Poisson regression. All associated factors in 
univariate analyses with a p value less than 0·10 and factors known from clinical experience to influence the outcome were entered in 
the model. A step-wise selection of the variables was applied to develop a score for the primary endpoint according to the number of 
risk factors present. The optimal threshold defining high versus low values for each continuous variable in the final model was obtained 
using the Hothorn and Zeiles method. All tests were two-sided and p values 0·05 or less were deemed to indicate a significant 
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association. Analyses were done using SPSS, version 22.0, and R, version 3.2.3. This trial is registered with ClinicalTrials.gov, number 
NCT00297193 
Role of the funding source 
The Broad Foundation reviewed and assessed the original grant application. Co-authors who were members of EBMT or ECCO 
had full access to all the data in the study and had final responsibility for the decision to submit the manuscript for publication. 
Results 
Between June 28, 2007, and Sept 1, 2011, 45 patients were enrolled and randomly assigned to either conditioning with stem cell 
rescue (n=23) or conventional care (n=22) in the ASTIC trial.14 Of 22 patients assigned to receive conventional therapy during 
the ASTIC trial, 17 went on to receive HSCT after completion of the trial (one patient withdrew, three underwent surgery, and 
one had im-proved on conventional therapy; figure 1). Of 23 patients who underwent HSCT in the ASTIC trial, 21 had available 
data at 1 year (one died at 20 days after conditioning and one withdrew at 26 weeks). Therefore, for this analysis, data were  
available for 40 patients at baseline and 38 patients at 1 year. The final date of follow-up included in this analysis was Feb 4, 
2014. The median disease duration was 15·04 years (IQR 9·19–16·82; table 1). All but one patient (oesophageal disease only) 
had colonic or ileo-colonic involvement. At baseline, patients had markedly active disease with a mean CDAI of 332·6 (SD 
111·36) and PRO-2 of 23·85 (10·35; table 1). There was evidence of active disease in all patients and the mean SES-CD was 14·03 
(SD 8·96). 
The primary outcome of steroid-free clinical remission for 3 months occurred in 13 (38%, 95% CI 22–55) of 34 patients. 12 
(35%, 19–51) of 34 patients were in remission for 3 months off all medical therapies, and 16 (43%, 27–59) of 37 patients were in 
steroid-free remission at 1 year.  
Complete endoscopic healing was achieved in 19 (50%; 95% CI 34–66) of 38 patients, and partial endoscopic healing was 
achieved in 31 (82%; 69–94) of 38 patients (figure 2). 18 (47%; 31–63) of 38 patients were judged free from evidence of intestinal 
ulceration on endoscopic and radiological assessment at 1 year. 
HSCT resulted in a significant improvement in clinical disease activity with a reduction in mean CDAI from baseline to 1 year 
(336·7 [SD 112·26] to 196·0 [133·29]; p<0·0001). This improvement was evident at week 6 (CDAI 212·3 [SD 128·36]; 
p<0·0001 compared with baseline), at which time 15 (38%; 95% CI 21–54) of 39 patients were in clinical re-mission (CDAI <150; 
figure 3). HSCT improved disease-specific quality of life with a significant increase in mean IBDQ from baseline to 1 year (119·66 
[SD 33·54] to 152·23 [45·15]; p<0·0001). There were similar signifi-cant improvements baseline to 1 year in EQ5D (0·75 
[0·10] to 0·80 [0·16]; p=0·0330), EQ-VAS (53·55 [21·42] to 72·72 [22·50]; p=0·00016), and PRO-2 (24·03 [10·56] to 12·45 
[9·78]; p<0·0001) scores (table 2).  
There was a significant improvement in endoscopic disease activity with a reduction in mean total SES-CD from baseline to 1 
year (14·1 [SD 9·03] to 5·4 [6·57]; p<0·0001, table 2). Complete endoscopic disease regression was seen in ten (26%; 95% CI 12–
40) of 38 patients. The effect of HSCT on individual ileal and colonic segments is shown in the appendix (p 1). Disease in the 
small bowel proximal to the ileum was present in seven (18%; 95% CI 6–31) of of 38 patients with data at 1 year, of whom five 
(71%; 39–100) were judged free from disease in this location at 1 year. HSCT had no effect on perianal disease (data not shown). 
In the year after HSCT, reintroduction of anti-TNF therapy was required in seven (18%; 95% CI 6–31) of 38 patients who 
completed HSCT after a median of 18 weeks after HSCT (range 14–39). This treatment resulted in a significant reduction in mean 
CDAI (319 [SD 124·17] to 174 [87·52]; p=0·016), and five (71%; 95% CI 38–100) of seven patients who had anti-TNF treatment 
had a clinical response (reduction of CDAI >70 points). 
On univariate analysis, categorical variables signifi-cantly associated with higher rate of 3-month steroid-free remission at 1 
year were disease localisation (colonic disease) and disease behaviour at baseline (inflammatory phenotype; appendix p 2), and 
continuous variables were shorter time from diagnosis to HSCT, lower baseline CDAI, and higher baseline SES-CD (appendix p 
3). 
After multivariate analyses, factors associated with steroid-free remission for at least 3 months were shorter time from diagnosis 
to HSCT (odds ratio [OR] 0·64, 95% CI 0·41–0·997 per year; p=0·048), and lower baseline CDAI (0·82, 0·74–0·98 per 10 units; 
p=0·031). Higher baseline SES-CD (0·85, 95% CI 0·71–1·002; p=0·053 per unit) seemed to be associated with the primary endpoint 
but was not statistically significant. The optimal thresholds were 298·3 for CDAI, 17 for SES-CD, and 11·24 months for time 
from diagnosis to HSCT. This allowed a prognostic score to be devised based on the number of predictive factors present at 
baseline (appendix p 4), leading to a receiving operating characteristic area under the curve (ROC AUC) of 0·948 (0·874–1·0). 
Univariate analysis identified low haemoglobin (mean 12·0 g/dL [SD 1·33] vs 12·9 g/dL [1·17]; p=0·029), high CRP (31·95 mg/L 
[SD 31·78] vs 15·49 mg/L [13·63]; p=0·063), and a short time from diagnosis to HSCT (12·1 years [SD 3·9] vs 16·3 years [7·0]; 
p=0·026) as baseline factors positively associated with complete endoscopic healing. However, no factors remained signifi-cant in 
multivariate analysis. Likewise, by uni-variate analysis, low haemoglobin (12·0 g/dL [SD 1·37] vs 12·9 g/dL [1·16]; p=0·038), high 
CRP (31·95 mg/L [32·82] vs 16·42 mg/L [13·78]; p=0·094), and a short time from diagnosis to HSCT (11·88 years [3·93] vs 16·27 
years [6·81]; p=0·021) were baseline factors associated with being adjudicated free of all active disease at 1 year. However, no factors 
remained significant in multivariate analysis. 
Serious adverse events were common in patients undergoing HSCT (23 of 40 patients with available data had 76 serious adverse 
events. 48 out of the 76 events were designated as related to treatment; table 3). The most frequent serious adverse events both 
during the 100 days after conditioning and the subsequent follow up were infectious, related to treatment. There was a reduction 
in the incidence of serious adverse events during the course of the trial. Univariate analysis suggested that patients with perianal 
disease at baseline might be more likely to experience at least one serious adverse event, but this result was not statistically 
signifi-cant (81·8% vs 48·3%; p=0·079). By contrast, univariate analysis identified increased numbers of serious adverse events in 
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current smokers (4 [SD 3·96] vs 1·38 [SD 2·1]; p=0·011), patients with perianal disease at base-line (4·09 [3·96] vs 1·07 [1·49]; 
p=0·0004), and patients who received conditioning and HSCT immediately after mobilisation (2·61 [3·31] vs 0·94 [1·20]; 
p=0·01), compared with participants who did not meet these criteria. Multivariate analysis identified that smoking and perianal 
disease at baseline were independent factors associated with the number of serious adverse events (OR 3·07 [95% CI 1·75–5·38; 
p=0·0001] for smoking and 3·97 [2·17–7·25; p<0·0001] for perianal disease). 
Discussion 
Our results show significant improvements in 3-month steroid-free remission, quality of life, and both clinical and endoscopic 
disease activity 1 year after HSCT in patients with treatment-refractory Crohn’s disease. 
To our knowledge, these data represent the largest reported cohort of patients with treatment-refractory Crohn’s disease to 
under-go HSCT to date. These data add important infor-mation to the randomised controlled ASTIC trial14 because we assessed 
endpoints that are more traditional for clinical trials in refractory Crohn’s disease and include data from patients who underwent 
HSCT after the primary endpoint for the controlled trial had been assessed. 
In the ASTIC controlled trial, few patients in either group achieved the ambitious primary endpoint of sustained disease 
remission at 1 year, with no use of corticosteroids, immunosuppressive drugs, or biological drugs, and no endoscopic or 
radiological evidence of active disease (ie, cure); there was a high burden of serious adverse events and one patient died from 
sinusoidal obstructive disease after conditioning. As such it has been reported as a negative trial.14 Several important issues have 
been raised that affect interpret-ation of the benefit of HSCT in the ASTIC trial.22,23 The predefined primary endpoint was the 
most stringent ever used for a clinical trial in Crohn’s disease. The low number of patients who achieved this outcome indicates 
that cure is not a common outcome and that the trial might have been underpowered to detect a difference in this endpoint. 
However, a signifi-cant benefit of HSCT versus mobilisation alone was noted for individual components of the primary outcome. 
Finally, the ASTIC trial recruited a treatment refractory cohort with heterogeneous disease distribution, many of whom would 
not meet the inclusion criteria for conventional clinical trials (for example, six patients had  diverting or permanent ileostomies). 
Assessment of baseline and 1-year outcome from the combined group of patients in the ASTIC trial irrespective of timing of 
HSCT allowed a better assessment of the effect of stem-cell transplantation. Importantly, sufficient numbers of patients were 
included to identify factors that might predict clinical benefit. The potential for bias inherent in an open-label assessment is 
reduced by the robust nature of the data collection and monitoring that was required for a controlled trial. All endoscopic and 
radiological investigations were reviewed and scored by an adjudication panel that was masked to the timing of the assessment  
and the treatment assignment of the patient. The present analysis shows that HSCT is associated with an early and sustained 
reduction in clinical disease activity, and allowed withdrawal of steroid therapy. Patient-reported outcomes and assessment of 
both disease-specific and generic quality of life mirror the improvements in disease activity. Endoscopic disease activity was 
significantly reduced, and complete endo-scopic healing was achieved in half the patients at 1 year. Complete healing throughout 
the entire intestine was observed in just under half the patients. These figures com-pare favourably with reports of clinical and 
endo-scopic outcomes from currently licensed and emerging biological therapies.24–28 
Univariate analyses highlighted baseline factors associated with achieving steroid-free clinical remission for longer than 3 
months. Associated factors included colonic disease, short disease duration, evidence of inflammatory rather than complex 
disease, and high endo-scopic burden of disease activity. High baseline CDAI was a negative predictive factor, which might 
reflect the fact that patients with advanced disease have structural damage to the intestine that drives non-inflammatory 
symptoms. This concept is supported by the fact that several patients with no change in their CDAI during the trial had complete 
regression of intestinal ulceration on radiology and endoscopy at 1 year. Multivariate analysis confirmed the independence of 
disease duration, endoscopic evidence of disease activity, and a lower baseline CDAI. This confirmation allowed a predictive 
model to be constructed, although this is likely to be of little clinical utility because only patients with active disease refractory 
to available biological therapies would be likely to be considered for HSCT. 
All patients were intolerant or refractory to at least one anti-TNF drug before entering the trial. Patients who had a disease 
flare after HSCT were able to recommence anti-TNF therapy, resulting in a significant reduction in disease activity and most 
patients having short-term clinical remission. Further study is required to establish the mechanism by which previous loss of 
response or intolerance to therapy is overcome, and assess the benefit of routine maintenance therapy after HSCT.  
Many patients had serious adverse events throughout each phase of the trial, highlighting the importance of careful patient 
selection. The incidence of serious adverse events reduced during the course of the trial implying that centres became more 
proficient at managing HSCT with experience.29 Patients in both groups received 4 g/m² cyclophosphamide at mobilisation. 
Although this was accepted practice at the start of the trial,15 lower intensity mobilisation regimens are recommended to reduce 
the toxicity of the procedure.10,22 Patients who proceeded immediately to conditioning and stem-cell rescue had a greater number 
of serious adverse events on univariate analysis, probably due to the additional doses of cyclophosphamide received within in a 
short time frame. Smoking and perianal disease were independent risk factors for an increased number of serious adverse events. 
Studies of HSCT in other diseases have also reported that smoking is a risk factor for adverse events.30 An understanding of factors 
that predict risk should influence the design of future research to establish whether lower-intensity regimens deliver similar benefits 
with reduced risks. Subsequent trials should consider straight random-isation between low-dose mobilisation and HSCT versus 
standard care to give an accurate com-parison between HSCT and best medical therapy. 
The data from this cohort represent the largest report of patients with refractory Crohn’s disease undergoing autologous HSCT. 
These data show significant benefit from HSCT in terms of steroid-free clinical remission, enhanced quality of life, and mucosal 
healing. The large number of serious adverse events suggests that this treatment strategy should only be considered in patients 
who are refractory to biological therapies. Identification of factors that predict both benefit and harm will be invaluable in the 
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design of future trials. Such trials should assess whether the use of low-intensity mobil-isation and conditioning regimens can 
maintain the observed benefit while reducing the risk of HSCT. 
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